Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients

Drug Safety

Volumn 25, Issue 10, 2002, Pages 725-733

  Pautas, Eric ^a   Gouin, Isabelle ^a   Bellot, Oliver ^a   Andreux, Jean Paul ^a   Siguret, Virginie ^a  

^a HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; CREATININE; DIPYRIDAMOLE; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

AGE; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DOSE CALCULATION; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0036360980     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225100-00005     Document Type: Article

References (36)

1. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly
2. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications
3. Guide to anticoagulant therapy: Heparin
4. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
5. Treatment of deep venous thrombosis with low-molecular-weight heparins
6. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a metaanalysis
7. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis
8. A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
9. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: A meta-analysis
10. Heparin and low molecular weight heparins
11. Aging and the kidneys
12. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
13. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
14. Monitoring of low molecular weight heparins in cardiovascular disease
15. How and when to monitor a patient treated with low molecular weight heparin
16. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)
17. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment
18. Treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin in the geriatric patient population
19. Prediction of creatinine clearance from serum creatinine
20. Tinzaparin French summary product characteristics
21. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers
22. The pharmacodynamics of tinzaparin in healthy volunteers
23. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis
24. Elderly patients treated with tinzaparin (Innohep®) administered once daily (175 anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days
25. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependant factor of 25 patients with heparin-associated thrombocytopenia
26. Muscle hematoma in the very elderly receiving low-molecular weight heparins
27. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
28. A comparison of low-molecular-weight heparin for acute pulmonary embolism
29. Heparin induced thrombocytopenia: Minimising the risks in the elderly patient
30. Heparin-induced thrombocytopenia: A clinicopathologic syndrome
31. Oral anticoagulation in the elderly
32. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: A randomized trial
33. Home-LITE: Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low molecular weight heparin versus warfarin
34. Effects of a low molecular weight heparin on thrombus regression and recurrent thromboembolism in patients with deep vein thrombosis
35. Secondary prevention of venous thromboembolism: A role for low molecular weight heparin